not tagged
janssen
['solid tumor', 'biomarker', 'janssen', 'janssenglobal']
today at #asco22, we presented data from a tumor-agnostic study that spans a wide range of advanced or metastatic solid tumors characterized by specific gene alterations. learn more about the potential of precision medicine in treating biomarker-driven cancers.
At Janssen, we never stop working toward a future where disease is a thing of the past. Channel run by Janssen Global Services LLC, NJ, USA.